Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Advancing Access to Lung Cancer Care Through Artificial Intelligence InnovationAdvancing Access to Lung Cancer Care Through Artificial Intelligence Innovation Tue, 10/13/2026 - 08:00 Body Originally published on preventcancer.org This post has been sponsored by Bristol Myers Squibb as part of its sponsorship of the 2026 Prevent Cancer Gala. Can AI help close care gaps in lung cancer? Lung cancer remains the leading cause of cancer death in the United States, with the American Cancer Society projecting about 229,000 new diagnoses and 125,000 deaths in 2026 alone. Behind those numbers lies another part of the story: Medically underserved communities, including many rural areas, experience higher mortality rates for lung cancer and are also less likely to undergo routine screening or biomarker testing. At Bristol Myers Squibb (BMS), we believe artificial intelligence (AI) can help identify and quantify these health care gaps, accelerate individual diagnosis, detect disparities in treatment pathways, predict risk of outcomes and proactively target interventions. Two ongoing collaborations help demonstrate this approach. Catching cancer earlier BMS shares the Prevent Cancer Foundation’s goal to increase awareness about the importance of lung cancer screening to enable earlier detection and better outcomes. However, lung cancer nodules can be small and easily overlooked, and they are sometimes found by chance on imaging done for unrelated reasons. Even when a nodule is spotted, more than half of these patients don’t receive proper follow-up care and may never actually see a specialist. These challenges present an opportunity for improvement that BMS is tackling through our collaboration with Microsoft. Using AI algorithms that are cleared by the U.S. Food and Drug Administration (FDA), and deployed through Microsoft’s extensive Precision Imaging Network, will help radiologists analyze X-ray and CT images to flag hard-to-detect nodules. Then, workflow tracking tools will help ensure patients flagged with nodules are connected to care rather than fall through the cracks. This multi-year collaboration is currently in its first phase, recruiting pilot sites such as rural hospitals and community clinics. Supporting better treatment decisions after diagnosis A second opportunity begins after diagnosis. For patients with advanced non-small cell lung cancer (the most common form of lung cancer), selecting the most effective therapy depends on biomarker testing. These lab analyses identify specific genetic mutations driving a patient’s cancer. But biomarker testing doesn’t always happen as guidelines recommend, in part because lab and electronic health record systems are often disconnected. Through our collaboration with Tempus AI, BMS implemented the AI-enabled Tempus Next Pathways program across 13 community-based health systems to build a near real-time view of the patient journey, finding out where and why patients were not receiving the right care according to guidelines. The results were compelling. By providing these insights to clinical teams, guideline-directed biomarker testing rates rose from 73% to 84% across participating sites. The program also helped explain the reasons behind that gap, such as clinical factors like disease progression or transitions to hospice care, or logistical issues like patients relocating out of their previous health system. This information provided better tools to design targeted interventions. Two projects, one purpose Together, these two projects present a picture of what AI-enabled, data-driven and access-focused cancer care can look like: identifying cancer earlier through smarter imaging workflows and enabling evidence-based treatment. For BMS, that combination reflects a broader commitment, one shared with organizations like the Prevent Cancer Foundation, to help innovation in cancer care reach every community. Learn more about Advancing population health – Bristol Myers Squibb Canonical URL https://preventcancer.org/article/advancing-access-to-lung-cancer-care-through-… Featured Image Type of Content Article
- Affinia TherapeuticsAffinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026WALTHAM, Mass., October 09, 2026--Affinia Therapeutics ("Affinia"), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that AFTX-201 preclinical and translational data and the Phase 1/2 UPBEAT™ clinical trial investigating AFTX-201 in patients with BAG3-associated dilated cardiomyopathy (DCM), will be featured at the Heart Failure So
- MedincellMedincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)MONTPELLIER, France, October 09, 2026--Medincell (Paris:MEDCL) Medincell will host Investor webcast today to discuss the implications of the approval for the Company and answer questions from analysts.
- Antibody Designed by Spanish Biopharma Oncomatryx Shows That Attacking the Tumor Environment Also Kills Cancer CellsZAMUDIO, Spain, October 09, 2026--Oncomatryx, the Basque biopharmaceutical company pioneering the treatment of solid tumors through their microenvironment, has taken part, together with German research institutions, in a study showing in patient tumor tissue that destroying the cells that protect the tumor also kills cancer cells.
- Milestone Pharmaceuticals Inc. MONTREAL andMilestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical TrialDutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR
- Nuvectis Pharma to Participate in the Maxim Growth Summit 2026Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York.
- Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical ConferencesEupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company’s ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis ("EoE") have been accepted and will be presented at: (i) the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting & Postgraduate Course, being held October 9-14, 2026 in Nashville, Tennessee, and (ii) the United European Gastroenterology (UEG) Week 2026, being held October 17-20, 2026 in Barcelona, Spain.
- Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary DiseaseCompany common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026
- Filana Therapeutics, Inc.Filana Therapeutics to Participate in the 2026 Maxim Growth SummitFilana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the Company’s management team will participate in the 2026 Maxim Growth Summit being held October 12-14, 2026 in New York.
- Advanced Technology Meets Best Urology Oncologists in IndiaUro-oncology treatments encompass a range of therapeutic approaches aimed at addressing cancers of the urinary system, including the bladder, kidneys, and prostate.
- Cadila Pharmaceuticals Earns Asia Book of Records Recognition for Nationwide Doctor Engagement Initiative· Achieved Global Milestone with Mass Graphology Campaign for Indian Medical Fraternity · An initiative celebrating clinicians’ selfless service and personal traits India’s leading global pharmaceutical manufacturer, Cadila Pharmaceuticals, has been officially recognized by the Asia Book of Records. This prestigious recognition follows a nationwide doctor engagement initiative that facilitated a handwriting analysis study involving […]
- Low Grade Serous Ovarian Carcinoma Market - Global Forecast by Therapy, Administration Route, and Country, 2025-2035 | Precision Oncology Unlocks GrowthMaximize ROI through biomarker-led therapies, priority-market expansion, optimized resource allocation, and strategic co-development or acquisitions